InMed Pharmaceuticals (INM) Free Cash Flow Growth (3y) (2022 - 2026)
InMed Pharmaceuticals (INM) Free Cash Flow Growth (3y) (2022 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.96 Bn | 43.00 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.23 Bn | 39.58 Bn | 2.15 Bn | 14.41% |
| 3 | Zoetis | 31.76 Bn | 30.08 Bn | 1.05 Bn | 216.31% |
| 4 | Takeda Pharmaceutical | 28.68 Bn | 22.88 Bn | 5.10 Bn | 4.08% |
| 5 | United Therapeutics | 22.27 Bn | 19.61 Bn | 683.80 Mn | 49.44% |
| 6 | Viatris | 18.69 Bn | 17.81 Bn | 1.46 Bn | -10.40% |
| 7 | Neurocrine Biosciences | 15.56 Bn | 15.17 Bn | 935.80 Mn | -9.38% |
| 8 | Elanco Animal Health | 11.78 Bn | 11.25 Bn | 798.00 Mn | 134.18% |
| 9 | Dr Reddys Laboratories | 10.13 Bn | 9.97 Bn | - | - |
| 10 | InMed Pharmaceuticals | 6.48 Mn | 1.24 Mn | - | 1.80% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -0.77% |
| Dec 31, 2025 | 4.32% |
| Sep 30, 2025 | 10.60% |
| Jun 30, 2025 | 24.39% |
| Mar 31, 2025 | 32.30% |
| Dec 31, 2024 | 8.61% |
| Sep 30, 2024 | 14.32% |
| Jun 30, 2024 | 19.78% |
| Mar 31, 2024 | 24.96% |
| Dec 31, 2023 | -0.82% |
| Sep 30, 2023 | -16.15% |
| Jun 30, 2023 | 16.17% |
| Mar 31, 2023 | -2.69% |
| Dec 31, 2022 | -9.05% |
| Sep 30, 2022 | 2.09% |